Effectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study
Fondaparinux
Tolerability
Enoxaparin sodium
DOI:
10.1007/s40801-021-00273-4
Publication Date:
2021-08-25T18:05:38Z
AUTHORS (12)
ABSTRACT
Fondaparinux is the first approved anticoagulant drug among factor Xa inhibitors, with proven effectiveness and safety in preventing deep vein thrombosis. However, limited data are available supporting benefit-risk profile of fondaparinux vs enoxaparin a real-world group Indian patients thrombosis.To compare tolerability symptomatic thrombosis long-term setting.Data from electronic medical records adult diagnosed prescribed (n = 503) or 508) as monotherapy were analyzed. Effectiveness was analyzed terms recurrence, duration, type event, bleeding events at initial hospitalization follow-up visits up to 3 months duration. Appropriate statistical methods used determine significance (p < 0.05) between two groups.The recurrence non-inferior (2.78%) when compared (3.76%), mean duration 47 48 days, respectively. The number (in days) not significant > 0.05). Major higher 3.17% than 2.19%, difference statistically 0.05).The weight-based, once-daily subcutaneous dose showed comparable twice-daily for management
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (29)
CITATIONS (3)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....